Assenagon Asset Management S.A. Buys 21,877 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Assenagon Asset Management S.A. raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 15.8% in the 1st quarter, HoldingsChannel.com reports. The firm owned 160,615 shares of the biopharmaceutical company’s stock after buying an additional 21,877 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Catalyst Pharmaceuticals were worth $3,977,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. State Street Corp boosted its position in shares of Catalyst Pharmaceuticals by 7.8% during the fourth quarter. State Street Corp now owns 6,907,622 shares of the biopharmaceutical company’s stock valued at $161,224,000 after buying an additional 502,235 shares during the last quarter. Deerfield Management Company L.P. raised its position in Catalyst Pharmaceuticals by 72.8% in the 3rd quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock valued at $98,003,000 after buying an additional 2,095,291 shares during the last quarter. Fundsmith LLP raised its position in Catalyst Pharmaceuticals by 24.2% in the 3rd quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock valued at $66,267,000 after buying an additional 654,721 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Catalyst Pharmaceuticals by 11.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock valued at $76,035,000 after buying an additional 333,100 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Catalyst Pharmaceuticals by 21.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,996,297 shares of the biopharmaceutical company’s stock valued at $69,933,000 after acquiring an additional 538,128 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on CPRX. Zacks Research downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Citigroup lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $35.00 to $31.50 in a research report on Friday, May 8th. Weiss Ratings upgraded shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, June 3rd. HC Wainwright lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $35.00 to $31.50 in a research note on Thursday, May 28th. Finally, Wall Street Zen cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Catalyst Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $32.00.

Catalyst Pharmaceuticals Stock Down 0.1%

CPRX opened at $31.46 on Tuesday. Catalyst Pharmaceuticals, Inc. has a twelve month low of $19.05 and a twelve month high of $32.56. The company’s 50-day moving average price is $30.49 and its two-hundred day moving average price is $26.29. The stock has a market cap of $3.85 billion, a price-to-earnings ratio of 18.08, a PEG ratio of 0.96 and a beta of 0.74.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).